What's Going On With Bristol Myers Squibb Stock On Monday?

1. BMY's Breyanzi met primary endpoint in MZL cohort for lymphoma treatment. 2. Breyanzi has a significant overall response rate and good safety profile. 3. FDA previously approved Breyanzi for multiple types of B-cell malignancies. 4. A lawsuit against Bristol-Myers Squibb was dismissed, reducing legal concerns. 5. BMY stock price dropped 2.87% despite strong trial results and legal win.